Pancreas Club, Inc.
Atlanta Hilton & Towers
May 20, 2001

Program Schedule

7:00 am  Continental Breakfast  Grand Salon East

7:30 am  Registration

SCIENTIFIC SESSIONS
Grand Salon East

7:55 am  Welcome and Introductory Remarks
L. William Traverso, M.D., Virginia Mason Medical Center, Seattle, WA
William H. Nealon, M.D., University of Texas Medical Branch, Galveston, TX

Session I
BASIC STUDIES PANCREATIC CANCER
8:00 AM – 9:45 AM
(Speaker Ready Room - Walton Room)

Moderators:  Claudio Bassi, M.D., University of Verona, Verona, Italy
Gregory G. Tsiotos, M.D., University of Athens, Marousi, Greece

8:00 am  Human ductal pancreatic adenocarcinoma cells can be targeted and
destroyed by a rat insulin promoter-thymidine kinase construct, in vitro and
in vivo.  Thomas A. Tirone, Xiao Ping Wang, Nancy S. Templeton, F. Charles
Brunicardi, Michael E. DeBakey Department of Surgery, Baylor College of
Medicine, Houston, TX

8:10 am  Discussion

8:15 am  Intraductal papillary mucinous neoplasms of the pancreas: A commonly
recognized clinicopathological entity in the 1990s.  Sohn TA, Hruban RH,
Cameron JL, Lillemoe KD, Yeo CJ.  Department of Surgery, The Johns Hopkins
Medical Institutions, Baltimore, MD

8:25 am  Discussion

8:30 am  Insulin inhibits secretin-induced pancreatic bicarbonate output via
cholinergic mechanisms.  Marissa Howard-McNatt, MD, Timothy Simon, MD,
Yuanhong Wang, MD and Aaron S. Fink, MD, Department of Surgery, Atlanta
VA Medical Center and Emory University School of Medicine, Atlanta, GA
8:40 am  Discussion

8:45 am  **A 2030 D peptide as the putative pancreatic cancer-associated diabetogenic factor.** Mazza S., Basso D., Valerio A., Seraglia R., Greco E., Zambon C.F., Gallo N., Fogar P., Pedrazzoli S., Tiengo A., Plebani M. Departments of Laboratory Medicine, Clinical and Experimental Medicine, Medical and Surgical Sciences, University Hospital; Research National Council, Padova, Italy.

8:55 am  Discussion

9:00 am  **TIMP-1 antisense gene transfection decreases human pancreatic cancer growth and angiogenesis in a mouse model.** Mark Bloomston, M.D., Alexis Shafii, B.S., Amyn Rojiani, M.D., Ph.D., Alexander S. Rosemurgy, M.D.

9:10 am  Discussion

9:15 am  **Pancreatic cancer: Correlation between cell motility and prognosis.** C. Bassi, C. Laudanna, M. Falconi, R. Salvia, I. Frigerio, C. Sorio, A. Scarpa, and P. Pedrazzoli, The Departments of Surgery and Pathology, University of Verona, Verona, Italy.

9:25 am  Discussion

9:30 am  **High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.** Sohn TA, Su GH, Ryu B, Kern SE, Yeo CJ. Departments of Surgery and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD.

9:40 am  Discussion

9:45 am  **WILLIAM R. SCHILLER**

**“MARION ANDERSON - A REMEMBRANCE”**

9:55 am  BREAK  Grand Salon East

10:00 am  **HOW I DO IT?** - Imaging of Benign and Malignant Pancreatic Disease: The Year 2001

**Moderator:** Charles J. Yeo, MD, Johns Hopkins Medical Institutions, Baltimore, MD

**Participants:**

Karen M. Horton, MD, Johns Hopkins Medical Institutions, Baltimore, MD

"Computed Tomography"

Maurits J. Wiersema, MD, Mayo Clinic, Rochester, MN

"Endoscopic Ultrasonography"

Caroline Reinhold, MD, Montreal General Hospital, Montreal, Canada

"Magnetic Resonance Imaging"
Naomi Alazraki, MD, Atlanta VA Medical Center/Emory University, Atlanta, GA
"PET Scanning"

11:00 am POSTER SESSION
12:00 pm LUNCH

Session II
ACUTE PANCREATITIS
1:00 PM – 2:45 PM

(Speaker Ready Room - Walton Room)

Moderator: Michel Murr, M.D., University of South Florida, Tampa, FL
Lawrence Rosenberg, M.D., Montreal General Hospital, Montreal, Quebec, Canada

Department of Surgery and Pancreatitis Research Lab, University of South Florida, Tampa, FL

1:10 pm Discussion

Academic Unit of Surgery, B Floor, Clarendon Wing, The General Infirmary, Great George Street, Leeds, United Kingdom

1:25 pm Discussion

1:30 pm Macrophage depletion diminishes acute pancreatic inflammation and immune responses in adenoviral vector induced pancreatitis. A. Shifrin, N. Chirmule, S. Raper, Department of Surgery, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA

1:40 pm Discussion

1:45 pm Does extent of necrosis or development of infected necrosis influence morbidity mortality in necrotizing pancreatitis? Alexander Perez, Edward E. Whang, David C. Brooks, Francis D. Moore Jr., Michael D. Hughes, Gregory T. Sica, Michael J. Zinner, Stanley W. Ashley, Peter A. Banks, Center for Pancreatic Disease, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

1:55 pm Discussion

Improved prediction of outcome of severe acute pancreatitis by the Apache-II score at 48 hours after admission compared with the Apache-II score at admission. Arif A. Khan, Young Cho, Richard Ruiz, Anna Kaminski, Robert R. Selby, Nicolas Jabbour, Yuri S. Genyk, Rodrigo Mateo, Dilip Parekh. Department of Surgery, University of Southern California, Los Angeles, CA

Paracrine and systemic secretion of pro-inflammatory cytokines by the liver in experimental acute pancreatitis. T. Keck, J.H. Balcom, B.A. Antoniu, A.L. Warshaw and C. Fernández-del Castillo. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Preoperative ERCP can direct choice of modality for treating pancreatic pseudocysts (Surgery vs. Percutaneous drainage). W.H. Nealon, E. Walser, Department of Surgery, The University of Medical Branch at Galveston, Galveston, TX

A Phase I trial of preoperative gemcitabine and radiotherapy followed by postoperative gemcitabine for patients with localized, advanced, potentially resectable pancreatic adenocarcinoma. J.P. Hoffman, C.J. McGinn, E. Ross, S. Litwin, C. Szarka, P. O'Dwyer, J. Morphis, H.S. Cooper, W. Pinover, G.M. Freedman, N. Merapol, S. Nicol. Fox Chase Cancer Center, University of Michigan Cancer Center, Eli Lilly & Company

Pathologic variables important in the design of clinical trials of extended lymphadenectomy for pancreatic adenocarcinoma-experience with 124 patients. CC Barnett, EK Abdalla, SA Ahmad, KR Cleary, JN Vauthey, JE Lee, DB Evans, and PWT Pister. Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX


Laparoscopic pancreatic surgery for benign pancreatic tumors. Laureano Fernández-Cruz, E. Astudillo, A. Sáenz, J.P. Pantoja, S. Navarro. Hospital Clinic. Institute of Digestive Diseases, Department of Surgery, University of Barcelona

Mucus in the pancreatic duct is a predictor of survival and benign disease after resection for intraductal papillary mucinous tumor of the pancreas. Yuichi Kitagawa, Trisha A. Unger, Richard A. Kozarek, and L. William Traverso. Department of General Surgery, Virginia Mason Medical Center, Seattle, WA

BUSINESS MEETING

End of Conference

Cocktails and Dinner
Presidential Court
ABSTRACTS ACCEPTED FOR POSTER PRESENTATION

1) Carcinoma of the body and tail of the pancreas: has there been any improvement over the past decade? A analysis of 215 patients. C. Bassi, M. Falconi, W. Mantovani, R. Bettini, G. Talamini*, P. Pederzoli. Departments of Surgery and *Gastroenterology, University of Verona, Verona, Italy

2) Two subgroups of pancreatic non-functional endocrine tumors identified by genome-wide chromosomal deletion mapping. C. Bassi, M. Falconi, C. Contro, L. Casetti, G. Rigaud*, P.S. Moore*, G. Zamboni*, and A. Scarpa*. The Departments of Surgery and *Pathology, University of Verona, Verona, Italy


4) Pancreatic tissue concentration of cefepime in experimental acute pancreatitis. Beat Gloor, Mathias Worni, Oleg Tcholakov², Christophe A. Müller, Markus W. Büchler and Waldemar Uhl. Department of Visceral and Transplantation Surgery, University Hospital of Bern, Bern, Switzerland and Pirogov Emergency Medical Institute, Sofia, Bulgaria²

5) Neural invasion of pancreatic cancer is an early event. A lesson for future research. Parviz M. Pour¹, Wataru Kimura², Keita Morikane², Wing-Chung Chan², ¹UNMC Eppley Cancer Center and Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE and ²Department of Surgery, University of Tokyo, Japan

6) The expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. Matthias Schneider ¹2, Jens Standop¹, Alexis Ulrich¹, Helmut Friess², A. Andrén-Sandberg³, Parviz Pour¹, ¹Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, ²Klinik fuer Visceral-und Transplantationschirurgie, Inselspital, University of Bern, Switzerland, ³Department of Surgery, University of Lund, Sweden

7) Antibodies to C-ErbB2 can discriminate between the normal and diseased pancreas and between chronic pancreatitis and pancreatic cancer. J. Standop, M.B. Schneider, R.E. Brandt, J. L. Wisecarver, and P.M. Pour UNMC Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-6805

8) Overexpression of C-ErbB2 in pancreatic cancer revisited. J. Standop, L.O. Murphy*, M. Andrianifahanan, N. Moniaux, M.B. Schneider, J.L. Wisecarver, J.A. Bridge, R.E. Brand, S.K. Batra, T.E. Adrian* and P.M. Pour UNMC Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-6805, *Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE 68178

9) Trail, a promising therapeutic agent for pancreatic cancer therapy. J. Standop, M.B. Schneider, A. Ulrich, R.E. Brand*, and P.M. Pour UNMC Eppley Cancer Center, and *Department of Gastroenterology, University of Nebraska Medical Center, NE 68198-6805
10) Role of 18-FDG-PET in preoperative evaluation of patients with cystic lesions of the pancreas. C. Sperti, C. Pasquali, G. Ferlin, G. Liessi, F. Chierichetti, S. Pedrazzoli. Department of Medical and Surgical Sciences, University of Padua, Padua, PET Center-Nuclear Medicine, and Radiology, Castelfranco Veneto General Hospital (TV), Italy.

11) CD44v10 favors fibronectin adhesion and characterizes metastatic pancreatic cancer cell lines. Navgalia A., Stefani A., Piva M.G., Bogar P., Basso, D., Plebani M., Pedrazzoli S. Departments of Laboratory Medicine, Medical and Surgical Sciences, University Hospital, Padova, Italy.

12) The role of pancreatic resection for metastatic tumors to the pancreas. C. Sperti, C. Pasquali, L. Pinciroli, A. Ferronato, S. Pedrazzoli, Department of Medical and Surgical Sciences, University of Padova, Italy.


14) Protease-induced leukocyte activation and impairment of microvascular perfusion mediate organ injury in acute pancreatitis. W. Hartwig, J. Werner, E. Ryschich, M.M. Gebhard, A.L. Warshaw, Ch. Herfarth, E. Klar. Departments of Surgery and Experimental Surgery, University of Heidelberg, Germany, and Department of Surgery, Massachusetts General Hospital, Boston, MA.


19) Fibrin sealant (TISSEEL®) fails to prevent leaks after pancreatic resection. Michael L. Eisenberg, Gudrun Aspelund, Dana K. Andersen. Department of Surgery, Yale University School of Medicine, New Haven, CT


21) Effects of enteral feeding on exocrine pancreatic secretion in the dog. S.G. de la Fuente, M. Miura, D.D. Lawson, M. Harris, E. Clary and T.M. Pappas. Department of Surgery, Duke University Medical Center and Veterans Affairs Medical Center, Durham, NC

22) A high activity polymorphism in the promoter region of the alcohol inducible enzyme cytochrome P450 2E1 in alcoholism and end organ disease. MT Cartmell1,3, H-U Schulz4, DA O’Reilly1,3, B Yang3, V. Kielstein5, S. Dunlop5, W. Halangk4, AG Demaine3, AN Kingsnorth1. Depts. Of Surgery1, Gastroenterology3 and Molecular Medicine4, Plymouth Postgraduate Medical School, Derriford Hospital, Plymouth, UK and Dept. of Surgery4, University of Magdeburg and Private Neurological Practice3, Magdeburg, Germany

23) Report of a trial of a leukotriene receptor antagonist in chronic pancreatitis in humans. Cartmell Mt1, O’Reilly DA1, Porter C1, Wright D1, Marner M2, Kingsnorth AN1. Departments of Surgery1 and Pharmacy2, Derriford Hospital, Plymouth, UK and Department of Mathematics and Statistics3, University of Plymouth, UK

24) A highly metastatic human pancreas cancer cell line over-expresses TRKB receptor tyrosine kinase. Wayne A I Frederick, Tom Wang, Yongde Bao, Marina Jean, Tienai Wu, Douglas B. Evans, Paul J Chiao, Departments of Surgical Oncology and Molecular & Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

25) Inhibition of constitutively activated RELA/NFκB suppresses metastasis to the liver in an orthotopic nude mouse model. Wayne A I Frederick, Qiang gong Dong, DB Evans, Paul Chiao, Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX USA

26) Cyclooxygenase-2 is overexpressed in chronic pancreatitis. W. Schlosser, S. Schlosser, M. Ramadani, F. Gansauge, S. Gansauge and H.G. Beger. Department of General Surgery, University of Ulm, Germany

27) Tissue specific vector gene delivery of pancreatic carcinomas. SM Vickers, MD, JG Wesseling, MD, M Amamoto, MD, DT Curie, MD. University of Alabama at Birmingham, Birmingham, AL

28) Complications of pancreaticoduodenectomy (PD) and their management. P. Hodul, J. Pickleman, G.V. Aranha, Department of Surgery, Loyola University Stritch School of Medicine, Maywood, IL
29) Alterations in insulin secretion of SSTR1 KO mice using the isolated perfused mouse pancreas model. M Norman, TA Tirone, X Wang, FC Brunicardi, Michael E. DeBakey
Department of Surgery, Baylor College of Medicine, Houston, TX

30) Influence of pancreatic enzyme content on the pathogenesis of acute pancreatitis. AMM Coelho, SN Sampietri, EE Abdo, JEM Cunha, MCC Machado, Department of Gastroenterology – University of São Paulo Medical School - Brazil

31) Unexpected effects of octreotide pretreatment in experimental acute pancreatitis. JEM Cunha, MZ Salem, MCC Machado, EE Abdo, AMM Coelho, SM Sampietri. Department of Gastroenterology – University of São Paulo Medical School - Brazil

32) Is trypsinogen activation peptides released in acute experimental pancreatitis proportional to pancreatic and extrapancreatic lesions? MCC Machado, AMM Coelho, SN Sampietri, KRM Leite, JEM Cunha. Department of Gastroenterology – University of São Paulo Medical School - Brazil


34) En-bloc SMV/Portal Vein resection in the treatment of pancreatic cancer: Implications for survival. SA Ahmad, EK Abdalla, CC Barnett, X Wang, KR Cleary, JN Vauthey, JE Lee, PWT Pisters, DB Evans. Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX


36) Gemcitabine increases toxicity without altering pancreatic cancer survival. Matthew I. Goldblatt, MD, Jason S. Duelge, MD, Beth A. Erickson, MD, Paul S. Ritch, MD, Michael J. Demeure, MD, Stuart D. Wilson, MD, Henry A. Pitt, MD. Medical College of Wisconsin, Department of Surgery, Milwaukee, WI

37) High failure rate in the diagnosis of pancreatic cyst tumors. Personal experience in 37 operated patients. Andrea Di Giorgio MD, Sergio Alfieri MD, Fabio Rotondi MD, Paola Caprino MD, Giovanni Battista Doglietto MD. Department of Digestive Surgery, Catholic University – Gemelli Hospital – Rome, Italy

38) Intraoperative and post-operative radiation therapy improve clinical outcome after pancreateoduodenectomy for head pancreatic cancer. A multivariate analysis of 46 patients. Sergio Alfieri, MD, Andrea Di Giorgio, MD, Fabio Rotondi, MD, Paola Caprino, MD, Alessio Morganti*, MD, Numa Cellini*, MD, Giovanni Battista Doglietto, MD. Department of Digestive Surgery and *Radiotherapy, Catholic University, Gemelli Hospital, Rome - Italy